Xenon Pharmaceuticals Investor Presentation — December 2019

Document content

NASDAQ: XENE | www.xenon -pharma.com

Corporate Presentation

December 2019| SLIDE 2Forward Looking Statement/Safe Harbor

This presentation and the accompanying oral commentary contain forward -looking statements that involve risks, uncertainties and assumptions. If the risks

or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward -

looking statements. All statements other than statements of historical fact could be deemed forward -looking, including, but not limited to, statements

regarding our expectations regarding the timing of and results from clinical trials and pre -clinical development activities, inc luding those related to XEN1101,

XEN496, XEN007 and our other product candidates, along with those related to XEN901 and other pre -clinical compounds covered by our collaboration with

Neurocrine Biosciences, Inc.; the potential efficacy, safety profile, future development plans, addressable market, regulator y success and commercial

potential of XEN1101, XEN496, XEN007 , XEN901 and other product candidates, the anticipated timing of IND, or IND equivalent, submissions and the

initiation of future clinical trials for XEN1101, XEN496, XEN007, XEN901 and other product candidates, the efficacy of clinic al trial designs, our ability to

successfully develop and achieve milestones in the XEN1101, XEN496 , XEN007, XEN901 and other development programs, the desig n of clinical trials and

anticipated enrollment, and the progress and potential of other ongoing development programs.

These statements are based on estimates and information available to us at the time of this presentation and are not guarante es of future performance.

Actual results could differ materially from our current expectations as a result of many factors, including but not limited t o promising results in early clinical

trials may not be replicated in subsequent clinical trials; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product

candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed

to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered p rograms; the impact of

competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities

and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. Except as required by law, w e assume no obligation and